摘要
目的评价急诊经皮冠状动脉腔内成形术(PTCA)联合脂微球载体前列腺素E1(Lipo-PGE1)治疗急性心肌梗死的有效性和安全性。方法前瞻性研究117例行急诊经皮冠状动脉腔内成形术治疗的急性心肌梗死患者,随机分组后联合应用脂微球载体前列腺素E1者54例。结果117例患者中,梗塞相关血管再通111例(其中101例行支架置入),成功率94.9%。54例联合应用Lipo-PGE1的患者梗塞相关血管再通51例,成功率94.4%,术后半小时心电图ST段下降较未联合应用组明显,24小时心功能改善较显著,未出现血压、心率等不良改变。结论急诊PTCA联合脂微球载体前列腺素E1治疗急性心肌梗死可保护患者心功能,近期疗效较单纯急诊PTCA者佳,无不良副作用,展示了可喜的应用前景。
Objective To study the safety and efficacy of emergent PTCA combined with liposomal prostaglandinE1 （Lipo- PGE1 ） in the treatment of acute myocardial infarction. Methods The clinical information of 117 acute myocardial infarction patients who had been treated with emergent PTCA （54 cases of which were also used Lipo - PGE1 in the mean time） were analyzed retrospectively. Results The infarct vessels were re - open in 111 patients （ 101 cases were routinely placed transluminal stand）. The successful rate was 94.9%. Which of those who also used Lipo -PGE1 were re -open in 51 patients. The successful rate was 94.4%, their ST segments on EKG 30 minutes after operations reduced significantly than that of patients who did not use Lipo - PGE1, their cardiac functions were also improved significantly 24 hours after operations and no side effects on blood pressure and heart rate were observed. Conclusion The emergent PTCA combined with Lipo - PGE1 for acute myocardial infarction can protect patient＇ s cardiac function and shows a better early therapy effect. No side effect could be found. It shows that Lipo - PGE1 would has a good applying foreground.
出处
《现代医院》
2007年第10期20-22,共3页
Modern Hospitals
